Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study | Synapse
March 5, 2026Open Access
Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study
Key Points
To assess the clinical and cost-effectiveness of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome.
Multi-centre design
Open-label methodology
Single-arm approach
Evaluation of clinical outcomes and cost-effectiveness
Assessment of eculizumab withdrawal showed potential for cost savings
Clinical outcomes after withdrawal were monitored and assessed
Findings contribute to understanding treatment strategies in atypical haemolytic uraemic syndrome
Abstract
This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 15/130/94.